Cassava Sciences Inc (SAVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cassava Sciences Inc (SAVA) has a cash flow conversion efficiency ratio of -0.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.88 Million) by net assets ($68.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cassava Sciences Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Cassava Sciences Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Cassava Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cassava Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cassava Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bekasi Fajar Industrial Estate
JK:BEST
|
0.001x |
|
Global Self Storage Inc
NASDAQ:SELF
|
0.021x |
|
Hoang Quan Consulting Trading Service Real Estate Corp
VN:HQC
|
0.115x |
|
Uzma Bhd
KLSE:7250
|
0.074x |
|
Sanica Isi Sanayi A.S.
IS:SNICA
|
-0.015x |
|
Paragon Union Bhd
KLSE:9407
|
0.061x |
|
Nice D&B Co. Ltd
KQ:130580
|
0.023x |
|
Pancontinental Oil & Gas N.L. R
F:PUB
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Cassava Sciences Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Cassava Sciences Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Cassava Sciences Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $74.40 Million | $-32.25 Million | -0.433x | +45.98% |
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -186.46% |
| 2021-12-31 | $253.91 Million | $-30.20 Million | -0.119x | -103.73% |
| 2020-12-31 | $92.20 Million | $-5.38 Million | -0.058x | +48.69% |
| 2019-12-31 | $22.10 Million | $-2.51 Million | -0.114x | +53.19% |
| 2018-12-31 | $19.63 Million | $-4.77 Million | -0.243x | +71.38% |
| 2017-12-31 | $9.70 Million | $-8.24 Million | -0.849x | -29.37% |
| 2016-12-31 | $18.64 Million | $-12.23 Million | -0.656x | -112.94% |
| 2015-12-31 | $29.37 Million | $-9.05 Million | -0.308x | -29.31% |
| 2014-12-31 | $40.06 Million | $-9.55 Million | -0.238x | -65.75% |
| 2013-12-31 | $48.30 Million | $-6.95 Million | -0.144x | +73.65% |
| 2012-12-31 | $13.14 Million | $-7.17 Million | -0.546x | -9220.90% |
| 2011-12-31 | $44.39 Million | $-260.00K | -0.006x | -34.88% |
| 2010-12-31 | $32.93 Million | $-143.00K | -0.004x | +96.80% |
| 2009-12-31 | $108.25 Million | $-14.69 Million | -0.136x | -226.78% |
| 2008-12-31 | $104.29 Million | $11.16 Million | 0.107x | +398.57% |
| 2007-12-31 | $103.91 Million | $2.23 Million | 0.021x | +114.14% |
| 2006-12-31 | $77.92 Million | $-11.83 Million | -0.152x | -108.49% |
| 2005-12-31 | $63.36 Million | $113.23 Million | 1.787x | +612.48% |
| 2004-12-31 | $93.40 Million | $-32.57 Million | -0.349x | -30.19% |
| 2003-12-31 | $76.56 Million | $-20.51 Million | -0.268x | +13.20% |
| 2002-12-31 | $50.22 Million | $-15.50 Million | -0.309x | -63.67% |
| 2001-12-31 | $65.62 Million | $-12.37 Million | -0.189x | -100.90% |
| 2000-12-31 | $78.69 Million | $-7.39 Million | -0.094x | +68.16% |
| 1999-12-31 | $9.14 Million | $-2.69 Million | -0.295x | -- |
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassav… Read more